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Medical genomics and healthcare
U.S. Department of Energy Genome Programs 
http://genomics.energy.gov
 Emergence of medical genomics and 
healthcare
 Promises and expectations to future 
potential
 Interesting is the claim to a wholesale 
transformation
 What is the transformative potential 
of medical genomics for healthcare of 
common diseases?
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The case of asthma research
 Assumption: early stage innovation process mainly taking place in 
science
 Focus on common disease research
 Analysis of 13 review papers (1999-2008)
 9 interviews with asthma and/or genomics researchers
 How has genomics and asthma become linked?
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The innovation journey
 Innovation journey is a nonlinear process, taking place in 
recognizable phases (Van de Ven et al.1999)
(Sahal, 1985)
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The innovation journey in context
 The innovation journey is the cross section of the overall co-
evolutionary processes between technology and society (Rip and 
Schot 2002)
 Innovation journey refers to the emergence of underlying path-
dependencies (Rip and Schot 2002)
 An emerging innovation journey is constructed in processes of de 
–and realignment (Rip and Schot 2002)
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Emerging irreversibilities
 Investigation of emerging irreversibilities as a tool to follow the 
progress of the innovation journey
 Emerging irreversibilities; enable certain actions and cognitions 
while constraining others (Van Merkerk and Van Lente 2005; Van 
Merkerk 2008)
 Emerging irreversibilities can be traced through dynamics of 
expectations, agendas and actor arrangements (Van Merkerk 
and Van Lente 2005; Van Merkerk 2008)
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A genomic future for asthma research?
 Initially genetics is presented as adding new insights to 
existing approaches (innovation journeys):
 “The widely accepted paradigm is that environmental factors are 
important to the development of asthma, but one must be 
genetically predisposed to respond to environmental differences” 
(Los et al. 1999: 1210)
 “Genetic studies of asthma continue to provide insight into the 
pathophysiological mechanisms of the disease” (Wiesch et al. 
1999: 900)
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An emerging innovation journey in asthma research
 Soon a new journey is taking shape:
 “Asthma genetics has finally crossed the line from a fledgling to a 
mature discipline. (…) The wave of the future of asthma genetics 
will probably include studies that combine the power of genetic 
and genomics approaches that use genome-wide SNP data-
bases for gene searches and that tease out gene-gene and 
gene-environment interactions that are certainly involved in the 
manifestation of this complex disorder” (Wills-Karp and Ewart 
2004: 385-86)
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An emerging innovation journey in asthma research
 “This is an exiting time to be studying the genetics of asthma, with 
large-scale, collaborative, whole-genome association studies 
under way in the United States and Europe” (Moffatt 2008: 416).
 “The identification of ADAM33 represented a breakthrough 
because this gene pointed to potentially new pathogenetic 
pathways for asthma“ (Vercelli 2008: 175) 
 “This ultimately will results in a deep understanding of the 
aetiology of previously mysterious diseases such as asthma, 
leading to the real potential of prevention and cures” (Moffatt 2008: 
416). 
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The emergence of asthma/genomics innovation journey
 Effectively the new innovation journey is shaped 
through the dynamic of an emerging irreversibility
 Expectations: ‘deep understanding’, ‘real potential of 
prevention and cure’, ‘complete change in perspective’, ‘from 
a fledgling to a mature discipline’
 Actor arrangements: ‘Large-scale collaborative’
 Agenda: ‘Genome-wide association studies’, ‘omics’. 
‘systems biology’
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Transforming existing innovation journeys
 Definition of asthma:
 Existing innovation journey where asthma is defined in terms 
of clinical manifestations
 Transformed to a definition with emphasis on internal invisible 
gene-environment interactions
 Explanatory model:
 Existing innovation journey where asthma is explained 
through the hygiene and allergen hypotheses
 Transformed to a nonlinear endophenotype model of 
asthma’s
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Resistance and uncertainty
 Resistance from participants in other innovation 
journeys:
 “I think that genomics may become useful in certain diseases, 
but in highly complex diseases such as asthma (..) I think it will 
be impossible to find a batch of genomic testing that will reliably 
identify one phenotype or another” (asthma5 2009) 
 In addition uncertainty is emerging if the 
asthma/genomics innovation journey will live up to its 
initial promises:
 “I am more pessimistic than I was a few years ago” (asthma2 
2009)
1403/10/10
An emerging irreversibility within asthma research
Innovation journey 
of asthma research
Asthma and genomics
Stabilising space
Branching moment
Emerging irreversibility
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Future perspectives
 Approach this uncertainty through discursive psychology
 Turn to asthma researchers themselves: How do they deal with 
this uncertainty?
 What discursive practices are in use?
 What interactional goals are achieved?
 What are the implications for their own roles and 
responsibility?
 Investigate these discursive practices in interaction in an 
upcoming workshop
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Thank you.
Comments are also welcome at: 
l.bitsch@utwente.nl
